# Shahneen Sandhu

Source: https://onco.cc/people/sandhu-shahneen/  
OnCo record `sandhu-shahneen` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.

## Summary

Shahneen Sandhu is a medical oncologist and Lead for Genitourinary Oncology Theranostics at the Peter MacCallum Cancer Centre in Melbourne. She runs the medical oncology side of Peter Mac's theranostics programme, leading combination trials such as PRINCE and UpFrontPSMA that pair lutetium-177 PSMA-617 with androgen receptor pathway inhibitors, chemotherapy and immunotherapy. Her publications include the UpFrontPSMA trial of sequential lutetium-177 PSMA-617 and docetaxel against docetaxel alone in metastatic hormone-sensitive prostate cancer. She also contributes to melanoma and early-phase research.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac
- Specialisms: Prostate cancer; Theranostics; Melanoma; Early-phase trials

## Sources

- Peter MacCallum Cancer Centre: https://www.petermac.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- companies: [ANZUP Cancer Trials Group](https://onco.cc/companies/anzup/)

---
JSON: https://onco.cc/api/v1/entities/sandhu-shahneen.json